Waldenstrom Macroglobulinemia Clinical Trials

21 recruiting

Waldenstrom Macroglobulinemia Trials at a Glance

23 actively recruiting trials for waldenstrom macroglobulinemia are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Boston, Rochester, and Seattle. Lead sponsors running waldenstrom macroglobulinemia studies include Centre Hospitalier Universitaire, Amiens, Dana-Farber Cancer Institute, and Mayo Clinic.

Browse waldenstrom macroglobulinemia trials by phase

Treatments under study

About Waldenstrom Macroglobulinemia Clinical Trials

Looking for clinical trials for Waldenstrom Macroglobulinemia? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Waldenstrom Macroglobulinemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Waldenstrom Macroglobulinemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 2

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled7 locationsNCT07387471
Recruiting
Phase 2

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Waldenstrom Macroglobulinemia
Massachusetts General Hospital55 enrolled5 locationsNCT06561347
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 2

Epcoritamab in Previously Treated WM

Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia
BeiGene111 enrolled8 locationsNCT05640102
Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Chronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell Lymphoma+2 more
Mayo Clinic100 enrolled1 locationNCT06151730
Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies

Waldenstrom Macroglobulinemia
Fundación Española de Hematología y Hemoterapía1,000 enrolled51 locationsNCT05093153
Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Phase 1

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Phase 2

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Waldenstrom MacroglobulinemiaTreatment Naive
Christian Buske80 enrolled11 locationsNCT05099471
Recruiting
Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled8 locationsNCT07231952
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Not Applicable

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

Waldenstrom MacroglobulinemiaWaldenstrom's Disease
Centre Hospitalier Universitaire, Amiens90 enrolled1 locationNCT04893564
Recruiting
Phase 1

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Mantle Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Stanford University148 enrolled1 locationNCT06340737
Recruiting
Not Applicable

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Chronic Lymphocytic LeukemiaLymphomaFollicular Lymphoma+6 more
UNC Lineberger Comprehensive Cancer Center40 enrolled1 locationNCT06860880
Recruiting
Not Applicable

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia

Waldenstrom MacroglobulinemiaHyperviscosity Syndrome
Centre Hospitalier Universitaire, Amiens100 enrolled1 locationNCT04898647
Recruiting
Phase 2

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia
Shayna Sarosiek, MD36 enrolled4 locationsNCT05190705